[{"id":"650a3245-ab7f-45dc-abea-d78920524b59","acronym":"CADENCE","url":"https://clinicaltrials.gov/study/NCT02547987","created_at":"2021-01-18T12:19:44.573Z","updated_at":"2024-07-02T16:35:45.450Z","phase":"Phase 2","brief_title":"Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer","source_id_and_acronym":"NCT02547987 - CADENCE","lead_sponsor":"Mothaffar Rimawi","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/25/2019","primary_completion_date":" 06/25/2019","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-06-16"}]